Stratpharma AG
Modern Slavery Statement
Introduction
This statement is made pursuant to section 54 of the UK Modern Slavery Act 2015 and outlines the steps Stratpharma AG (including its subsidiaries) has taken to prevent modern slavery and human trafficking in our business operations and supply chain. While Stratpharma does not meet the reporting thresholds under the UK Modern Slavery Act or the Australian Modern Slavery Act, we voluntarily comply with these principles to ensure ethical standards in our business. This statement has been approved by the Stratpharma Board of Directors.
Our Business and Supply Chain
Stratpharma AG is a Switzerland-based company specializing in medical devices. Our supply chain involves the procurement of materials from a global network of suppliers. These materials are processed and assembled in various locations in Europe. We recognize that some regions present a higher risk of modern slavery and human trafficking, but we take steps to mitigate those risks through strict monitoring and control processes.
Compliance with International Standards
Stratpharma AG is ISO 13485 certified, ensuring that our supply chain and production processes follow stringent quality management and regulatory standards. Most of our suppliers comply with ISO 13485 ISO 9001 and other relevant international standards, which support adherence to quality management and ethical practices across our supply chain.
Policies and Governance
Stratpharma has implemented strict policies and procedures to prevent modern slavery and human trafficking. Our Employment Policy emphasizes the protection of workers' rights, health, and safety across all operations. We include clauses related to modern slavery in our supplier agreements to ensure compliance with human rights and labor laws.
Supply Chain Due Diligence and Risk Management
We undertake due diligence on our suppliers to assess risks of modern slavery, focusing on regions with higher risks. Our due diligence measures include obtaining Modern Slavery Declarations from key suppliers and conducting risk assessments where appropriate. Through our ISO 13485 certification, we ensure that suppliers are subject to regular audits and monitoring for compliance with ethical labor practices.
Training and Awareness
We provide basic training to employees on modern slavery risks, including how to recognize potential signs of exploitation. This training is reviewed and updated regularly to ensure that staff, particularly those involved in procurement and supply chain management, are equipped to address potential risks. In the future, we plan to enhance these training programs by incorporating emerging best practices in modern slavery prevention.
High-Risk Suppliers Focus
Stratpharma prioritizes monitoring high-risk suppliers and conducting more rigorous audits where necessary. Our focus on compliance with ISO 13485 and other international standards helps ensure that suppliers in these regions meet international standards for labor practices. During regular audits, we assess suppliers for any signs of unethical labor practices, including forced labor and human trafficking.
Collaboration and Future Plans
Stratpharma is committed to working with suppliers and other partners to prevent modern slavery. To date, we have had no reports of modern slavery within our business or supply chain. We remain vigilant and work closely with our suppliers to ensure continuous improvement in labor conditions and compliance with ethical standards. Our focus is on maintaining an open dialogue and supporting our suppliers in meeting the highest standards for worker welfare.
Conclusion
Stratpharma AG remains dedicated to ensuring that modern slavery and human trafficking are not present in our business or supply chain. Our ISO 13485 certification and the additional compliance of suppliers with international standards demonstrate our commitment to upholding ethical standards. We will continue to review and improve our policies and processes to ensure the highest standards across all our operations
Signed:
Luka Valas, Director & Corporate Secretary Stratpharma AG
On behalf of the Board of Directors of Stratpharma AG
October 1st, 2024